source
- UniQure submits experimental Huntington's gene therapy to FDA for accelerated reviewUniQure announced that it has filed its experimental gene therapy for Huntington's disease with the U.S. Food and Drug Administration, seeking accelerated approval. The submission follows earlier…
- Typewriter secures $56M to advance jumping-gene platform and in vivo CAR-T therapiesTypewriter, a biotech startup, announced it has closed a $56 million financing round. The capital will be used to develop its jumping-gene platform, which seeks to deliver full genes without viral…